This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
July 4, 2013 /PRNewswire/ --
Glioma Actively Personalized Vaccine Consortium (GAPVAC):14 organizations in Europe and the US join forces todevelop a completely novel approach to fight cancer
Multi-national clinical trial treating glioblastoma patients with fully personalized therapeutic vaccines planned to start in 2014
European Union supports GAPVAC with €6 million
A highly innovative project supported by a €6 million European Union Framework 7 (EU FP7) program grant to develop a novel class of therapeutic cancer vaccines is now under way.
Consortium (GAPVAC) is the first EU-funded initiative aimed at clinically developing biomarker-guided
actively personalized vaccines (APVACs) to treat cancer patients. The consortium consists of 14 organizations from the biotech industry and academia with cutting-edge expertise in cancer vaccine development. The consortium will be led by
immatics biotechnologies GmbH (Coordinator) and BioNTech AG (Vice Coordinator). Both companies are located in
Germany and are dedicated to a biomarker-guided approach to fight cancer.
The GAPVAC project is designed to create, manufacture and develop actively personalized vaccines (APVACs) tailored for each patient based on the individual aspects of the patient's tumor and immune system. The latest technologies, including next-generation sequencing (NGS), high-sensitivity mass spectrometry and innovative immunomonitoring approaches, will be combined to generate an optimal therapy for the individual patient.
GAPVAC will address the high unmet medical need in glioblastoma, an aggressive form of brain cancer with poor prognosis, where the limited treatments available today have minimal effect on overall survival. The project aims to show that APVACs are well tolerated and induce a strong and specific immune response against cancer. Furthermore, the partners will demonstrate that this novel personalized approach is feasible.